Compare PGEN & AVNW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PGEN | AVNW |
|---|---|---|
| Founded | 1998 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Radio And Television Broadcasting And Communications Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 278.2M |
| IPO Year | 2013 | 2007 |
| Metric | PGEN | AVNW |
|---|---|---|
| Price | $7.24 | $20.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $8.33 | ★ $34.50 |
| AVG Volume (30 Days) | ★ 6.0M | 121.8K |
| Earning Date | 05-13-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.03 | ★ 0.29 |
| Revenue | $230,981,000.00 | ★ $243,858,000.00 |
| Revenue This Year | $1,115.92 | $5.59 |
| Revenue Next Year | $81.04 | $7.03 |
| P/E Ratio | $248.00 | ★ $71.41 |
| Revenue Growth | N/A | ★ 0.56 |
| 52 Week Low | $2.99 | $13.92 |
| 52 Week High | $7.49 | $27.02 |
| Indicator | PGEN | AVNW |
|---|---|---|
| Relative Strength Index (RSI) | 66.39 | 47.38 |
| Support Level | $3.96 | $20.60 |
| Resistance Level | N/A | $22.59 |
| Average True Range (ATR) | 0.43 | 0.86 |
| MACD | 0.03 | -0.09 |
| Stochastic Oscillator | 88.73 | 15.87 |
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
Aviat Networks Inc provides wireless transport and access networking solutions designed to support telecommunications operators and private network providers situated in various countries. The company offers a range of microwave and millimeter wave radios, network management tools, and services that enable high-capacity, secure, and reliable data transport over wireless networks. Its products serve diverse clients including mobile operators, public safety organizations, utilities, government agencies, and enterprise customers. Aviat generates revenue from the sale of its networking equipment, professional services, and ongoing support contracts. Its operations cover various regions including the Americas, Europe, Asia Pacific, the Middle East, and Africa.